Several meta-analyses have demonstrated an association between reduced circulating levels of adiponectin and an increased risk of breast cancer, suggesting that it may serve as a biomarker for identifying individuals at high risk of developing breast cancer [27, 28]. This evidence concerns the gene ADIPOQ and breast carcinoma.